Newsletter

The Research Advocate, our award-winning membership newsletter, provides the latest news and information on medical, health and scientific research advocacy, as well as updates from Research!America. Regular features include policy updates, profiles of Research!America members, media coverage of research issues, a column by Research!America President and CEO Mary Woolley, and important updates to help our members in their own efforts to make research to improve health a higher national priority.

From Washington

Executive and Legislative Branches Focused on Making Strides in R&D

The 114th Congress was sworn in on Jan. 6 and with that began the cycle of annual congressional activity. New members of Congress have received committee assignments and some returning members have assumed new roles in the 114th Congress, particularly due to the new Senate majority. Key new committee assignments related to research span both authorizers and appropriators. On the Senate Appropriations Committee, Sen. Thad Cochran (R-Miss.) was confirmed as the chairman and Sen. Barbara Mikulski (D-Md.) remains the ranking member (the senior role in the minority party) of both the full committee and the Commerce, Justice, Science and Related Agencies (CJS) subcommittee, which has jurisdiction over funding for the National Science Foundation (NSF). Sen.Richard Shelby (R-Ala.) is the chairman of that subcommittee. Sen. Roy Blunt (R-Mo.) is chairman of the Labor, Health and Human Services, Education and Related Agencies (Labor-H) subcommittee (which has jurisdiction over funding for the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ)) and Sen. Patty Murray (D-Wash.) has assumed the role of ranking member on both Labor-H and the Health, Education, Labor and Pensions (HELP) Committee, which has authorization responsibility for NIH, CDC, AHRQ and theFood and Drug Administration (FDA). Sen. Lamar Alexander (R-Tenn.) is now chairman of HELP. Sen. Jerry Moran (R-Kan.) now serves as chairman for the Agriculture Appropriations subcommittee, which has jurisdiction over funding for FDA, along with ranking member Sen. Jeff Merkley (D-Ore.). Sens. Orrin Hatch (R-Utah) and Ron Wyden (D-Ore.) will continue to lead the Senate Finance Committee, which has tax writing authority, as chairman and ranking member, respectively. The House side has fewer changes, most notably on the Appropriations Committee: with Rep. Tom Cole (R-Okla.)leading the Labor-H subcommittee and Rep. John Culberson (R-Texas) leading the CJS subcommittee. Rep. Paul Ryan (R-Wis.) is now chairman of the Ways and Means Committee (the House counterpart to the Senate Finance Committee) while Rep. Tom Price (R-Ga.) has assumed the role of Budget Committee chairman. The ranking Democrats on those committees have not changed since last Congress. We look forward to working with each of these members to advance public- and private-sector funded research and development.

A 21st Century Cures legislation discussion draft was released to the public as a starting point for concrete conversations about how to modernize the discovery, development and delivery process in order to speed preventative measures, diagnostics, treatments and cures to patients. The initiative, championed by 2015 Whitehead Awardees Chairman of the Energy and Commerce Committee Fred Upton (R-Mich.) and Rep. Diana DeGette (D-Colo.), has helped keep research and patient-related issues front of mind during the new Congress.  The initiative welcomes input and asks that you send them your comments at:cures@mail.house.gov

This week, advocates received copies of the President's Budget, which enumerates the administration's priorities for FY16 and recommends easing the stringent sequestration budget caps that perpetuate artificially low discretionary spending. President Obama's proposal is a starting point for a major recommitment to medical progress.  The President focused on advancements in precision medicine, antibiotic and other anti-infective discovery, Alzheimer's research, and the BRAIN Initiative. Research!America is working with appropriators to push beyond what is probable and achieve what - if both parties and both branches are willing - is possible. Medical progress is a national strategic imperative, and it is time to treat it as one. 

Congress Mandates Blue Ribbon Panel on Science

How does science stack up among the priorities and concerns of U.S. citizens? A Blue Ribbon Commission mandated by Congress has been tasked with the job of discerning American public understanding and acceptance of scientific research. The Commission, to be managed by the National Academy of Sciences, will examine the present state of scientific repute in America and present recommendations for how to improve scientific literacy, education, and enhance scientific regard among Americans. Research!America played an integral role in getting the bill language establishing the Commission in the FY15 cromnibus bill and applauded members of Congress for elevating this issue on their, and nation's agenda.

FDA Commissioner Stepping Down

U.S. Food and Drug Administration (FDA) Commissioner Margaret Hamburg, M.D., will be leaving the agency this March, following six years of service. During her tenure, average FDA review times have been  faster than regulatory agencies in other countries, contributing to our nation's well-earned role of global leadership in innovation. Hamburg served as a panelist for Research!America's 2013 National Health Research Forum, where she expressed the need for a comprehensive, national strategy in the U.S. to better fund and support biomedical research. The FDA's chief scientist, Stephen Ostroff, M.D., will serve as acting commissioner.

"Dr. Hamburg's tireless efforts to streamline the drug approval process will leave a lasting imprint on patient care," said Mary Woolley, president and CEO, Research!America. "We are deeply grateful for her public service." 

New FASEB Report Explores Research Challenges

Insufficient federal funding and increasing regulatory costs are among the challenges facing researchers today according to a report from the Federation of American Societies for Experimental Biology (FASEB), a Research!America member. "Sustaining Discoveries in Biological and Medical Science: A Framework for Discussion"  explores the causes of the current instability in our nation's research enterprise. Recommendations fall under three categories including: optimize use of current funding resources, while advocating for predictable and sustainable funding for research; evaluate current research funding to reduce the amount of time spent acquiring funding and ensure that incentives are in place to promote the best possible science; and improve how the research workforce is prepared and utilized.

To view the report, and provide comments, visit www.faseb.org/SustainingDiscovery/Home.aspx.

America Lagging Globally in Research Investment

The United States' declining role as the world leader in research and development was highlighted in a paper in the Journal of the American Medical Association. The paper, "The Anatomy of Medical Research," calls attention to America's declining investment in research, with U.S. global share in research investment dropping from 57 percent in 2004 to 44 percent in 2012. This is also reflected in America's percentage of life science patents, which has dipped from 57 percent in 1981 to 51 percent in 2011, impacting America's ability to disperse biomedical research findings.

While America's investment in research is declining, other countries are ramping their R&D infrastructure up. Since 2004, China has tripled its investments from $1.6 billion to $4.9 billion.

To read the full paper, visit http://bit.ly/1DDIerP.

Vaccine Debate Gains Traction on Capitol Hill

Less than 60 percent of Americans are confident in the current system in the U.S. for evaluating the safety of vaccines, as well as recommendations for when they should be given, as compared to 85 percent in 2008, a steady decline over the last several years, according to national public opinion polls commissioned by Research!America. In 2014, a record number of measles cases was reported to the Centers for Disease Control and Prevention (CDC)  (644 cases from 27 states), and in January, 102 people from 14 states reportedly had measles (92 percent stemming from an outbreak at a California theme park).

Nearly 15 years ago, the United States declared that measles had been eliminated from the country, which the CDC credits to a highly effective measles vaccine and a strong vaccination program. As of last year, all 50 U.S. states allowed a medical vaccine exemption; 48 states allowed a religious vaccine exemption and 17 states allowed an exemption for philosophical, conscientious or personal beliefs. Lawmakers in several states are introducing legislation in an effort to address declining immunization rates. In recent interviews, Sen. Rand Paul (R-Ky.) said most vaccines should remain voluntary while New Jersey Governor Chris Christie noted that parents should retain some measure of choice. President Obama told NBC news that the science behind vaccines was "pretty indisputable,"  and the new U.S. Surgeon General Vivek Murthy, M.D., MBA, told CBS that he is "very concerned" about the current measles outbreak: "... if you don't get vaccinated and you're exposed to the measles, you have a 90 percent chance of catching the illness." Research!America board member Georges Benjamin, M.D., executive director, American Public Health Association, also weighed in on the issue, telling POLITICO Pro:  "I think we're all hoping that this ... will encourage people, particularly policymakers, to strengthen their vaccine laws and not weaken them and look very carefully at any exemptions they go to approve."  

From Research!America

Congressional Champions of Research to be Honored with Whitehead Award

When distinguished supporters of health and medical research gather next month to honor outstanding, notably effective advocates at the 2015 Research!America Advocacy Awards Dinner, two members of Congress will also be recognized for their commitment to advancing the discovery, development and delivery of lifesaving medical treatments. Chairman of the Energy and Commerce Committee Fred Upton (R-Mich.) and Rep. Diana DeGette (D-Colo.) will receive the Edwin C. Whitehead Award for Medical Research Advocacy, which epitomizes for both members of Congress a long record of leadership support for medical progress. Named in honor of Research!America founder, Edwin C. "Jack" Whitehead, the award recognizes exemplary leaders, particularly those in public office, who have demonstrated a deep commitment to advancing medical and health research as a national priority and who galvanize others in support of science.

"Representatives Upton and DeGette are remarkable stewards of our nation's research infrastructure, pushing boundaries to advance scientific knowledge and improve regulatory policies in order to speed medical advances to patients," said Research!America Chair John Edward Porter. "They work in a bipartisan manner to take on the urgent and monumental task of addressing barriers to innovation, an absolute necessity if we want to accelerate progress against deadly and disabling diseases."

The landmark 21st Century Cures initiative aims to speed up the development of new treatments by integrating the patient's perspective into the regulatory process, modernizing clinical trials, fostering the future of science, investing in research, incentivizing the development of new drugs and devices for unmet medical needs and facilitating data sharing and the use of new technologies.

"The 21st Century Cures initiative has relied on thoughtful feedback and support from groups like Research!America," said Rep. Upton. "My Democratic partner in this effort, Rep. Diana DeGette (D-Colo.), and I have been so encouraged by the outpouring of ideas and look forward to taking the next step in seeing those ideas become a reality. There are currently over 7,000 diseases yet we only have cures for 500 of them. This is unacceptable. By working together, our path to faster cures is clearer than ever."

"Our future is brimming with potential discoveries if we are willing to work to find them," said Rep. DeGette. "Biomedical research discoveries transform lives, so we must ensure researchers have adequate resources and an environment that delivers breakthroughs to patients. I am so grateful to have a passionate and dedicated partner in Congressman Upton who is committed to finding bipartisan ways to make biomedical research even better."

Research!America's 2015 Advocacy Awards dinner will be held on Wednesday, March 11, at the Mellon Auditorium in Washington, D.C. Other 2015 Advocacy Award winners include ABC's "Good Morning America" anchor Robin RobertsMichael Milken, founder of the Milken Institute and FasterCures;  Kenneth Olden, Ph.D., director, National Center for Environmental Assessment, U.S. EPADavid Van Andel, chairman and CEO, and George Vande Woude, Ph.D., founding scientific director, Van Andel Research Institute; and the Society for Neuroscience. For more information, visit www.researchamerica.org/advocacy_awards.

Fact Sheet Highlights Value of Dental Research

On Feb. 6, the American Dental Association (ADA) launched its 13th annual Give Kids a Smile program.  Not only does this initiative raise awareness about the alarming prevalence of dental caries (tooth decay) and other oral health issues, it deploys volunteers across the country to provide free dental care to those in need. Former U.S. Surgeon General David Satcher called tooth decay a "silent epidemic." Nearly 50 percent of all five-year-olds in the U.S. have experienced tooth decay, which is associated with an increased likelihood of developing cavities in their adult teeth. In 2012, total dental expenses for children in the U.S. aged 5-17 years were approximately $21 billion, with nearly 42 percent of dental costs paid out of pocket. In 2006, the ADA released a new vision statement for the Give Kids a Smile program with the goal of eliminating cavities in U.S. five-year-olds by 2020.

Research!America, in partnership with Colgate-Palmolive and the Children's Dental Health Project, have released a new fact sheet on children's dental health research that stresses the importance of investing in such research along with public health interventions focused on improving children's dental health. According to a Pew Center study, preventable oral health conditions result in an estimated 830,000 emergency room hospital visits each year. The U.S. Department of Health and Human Services estimates that there would be an additional 18.6 million Americans age 45 and older with none of their natural teeth if progress had not been made in understanding and treating dental caries and periodontal disease. Investments in dental and cross-disciplinary research have given us the tools to reduce the prevalence of childhood oral disease and continued investments will only further this progress. To view the fact sheet, visit http://bit.ly/DentalHealthResearch

Speeding Access to Treatment

Two-thirds of Americans say it's important for the 114th Congress to take action on assuring the discovery, development and delivery of treatment and cures for disease in the first 100 days of the legislative session, according to a new national public opinion poll commissioned by Research!America. Also, an increasing number of Americans believe the U.S. Food and Drug Administration (FDA) should move more quickly in order to get new treatments to patients, despite the potential risks, 38 percent compared to 30 percent in 2013. The poll also revealed that nearly 80 percent of Americans say it is important that our nation supports research to improve the functionality of our health care system, and more than half (53 percent) say it is important for Congress to make the R&D tax credit permanent to support businesses pursuing research and development activities. To view poll results, visit http://bit.ly/1C1H9o7.

Communicate the Value of Research

Instructors from across the research and academic communities will engage scientists, physicians, researchers and post-graduate academics on a number of topics during the professional development program, Connecting the Dots: Effectively Communicating Science to Non-Scientists, hosted by Research!America and The George Washington University (GWU) in April. The program is designed to enhance the ability of scientists to communicate their research to the public.

The instructors, who bring a variety of backgrounds and experience to the program, include several GWU professors and lecturers: David Karpf, Ph.D., author of The Move On Effect; Emily Thorson, Ph.D., strategic communications expert; Cheryl W. Thompson, Pulitzer Prize-winning investigative report for The Washington PostLauren Glickman, founder and principal, WindyGlick CommunicationsMaryanne Culpepper, former president, National Geographic Television; and Denise Cetta, producer, 60 Minutes.

Several Research!America board members will also serve as instructors and guest speakers: Susan Dentzer, senior health policy advisor, Robert Wood Johnson FoundationKeith Yamamoto, Ph.D., executive vice dean of the school of medicine, University of California, San FranciscoAlan Leshner, Ph.D., CEO, American Association for the Advancement of ScienceJay Gershen, DDS, Ph.D., president, Northeast Ohio Medical University; and Mary Hendrix, Ph.D., president, Lurie Children's Hospital of Chicago Research Center.

The program will be held on April 13-14, 2015 at the Milken Institute School of Public Health building on the Foggy Bottom campus of GWU. The deadline for applications is Feb. 6, 2015.

Visit www.researchameria.org/connectingthedots to learn more, or www.researchamerica.org/communicatingscience to apply.

Unsung Heroes of Public Health Awards

In recognition of the heroic efforts of the leaders in the public health community, the Campaign for Public Health Foundation (CPHF) held its fifth annual Unsung Heroes of Public Health Awards on Jan. 27 in Washington, D.C. While the awards highlight the efforts of just a few, it also brings to the forefront the efforts of the thousands of public health workers, many of whom operate behind the scenes, working to ensure our safety and that of our communities every day.

Michael Wahl, M.D., FACEP, FACMT, the medical director of the Illinois Poison Center in Chicago, Ill., is the recipient of the  Rock in the Pond Award, which recognizes individuals for outstanding work on a community-based or state-wide public health effort that produced significant positive health outcomes. Wahl has served as the director of the center since 1998, establishing the Poison Center Hotline, as well as similar hotlines for H1N1, MERS and Ebola.

Robert L. Burhans, former director of Health Emergency Preparedness at the New York State Department of Health, and Catherine C. Slemp, M.D., MPH, former state health officer and emergency preparedness director for the West Virginia Bureau for Public Health, are the winners of the foundation's Wavemaker Award. Burhans and Slemp were selected for their work on the development of the National Health Security Preparedness Index (NHSPI), which provides accurate and relevant information that can be used to increase health security preparedness.

CPHF has also awarded Donna A. Patterson, Ph.D., an honorable mention in the Excellence in Media Award category for her coverage of the Ebola outbreak in The Huffington Post. Patterson is an assistant professor in Africana Studies at Wellesley College in Wellesley, Mass., and specializes in the history of African medicine, pharmaceuticals and drugs.

The awards ceremony also containted a special presentation to former Executive Director Karl Moeller, in recognition of his 10 years of service to the foundation. 

Regular Features

President's Letter

We are excited about the rare, if not entirely unprecedented, race to take leadership in the Congress for research and innovation, seeking to improve health and drive the economy. Members on both sides of the aisle in both houses have introduced legislation or plan to do so. And meanwhile President Obama, in his FY16 budget proposal, has called for the end of sequestration and a down payment on making up for lost time in restoring our nation's science enterprise to the global leadership role we otherwise stand to lose, in not too many years. It is early in the new Congress, and the proposition that bipartisan action will go forward is still tentative indeed, but backbones can be stiffened if enough advocates speak up. Please make your voice heard! We can help. 

Advocates and advocacy matter. It's written into the First Amendment to the United States Constitution that the people have the right to advocate, based on the language "The right of the people ... to petition the government ... " When we honor this year's advocates at our event in Washington, D.C., on March 11, we will mark a long-standing tradition of saluting the organizations and people who make a difference to their fellow citizens and to society. Advocates inspire as well as accomplish. Please join us. I think you will find that even as you help celebrate, you will find yourself recommitting to making the case for the future of health and our economy by taking your place as an empowered advocate! 

Special Thanks to our Principal Partners and to New and Renewing Research!America Alliance Members

Research!America Extends Special Thanks to our Principal Partners

2015 Advocacy Awards

Tribute Reception Sponsor:
Pfizer Inc.
Benefactors:
The Gordon and Llura Gund Foundation
Rosenfeld Heart Foundation
Program Partner:
American Medical Association
Contributor:
Partners HealthCare System
Sponsors:
Bristol-Myers Squibb
United Therapeutics Corporation
University of California, San Francisco
Friends:
Washington University School of Medicine in St. Louis
Weill Cornell Medical College

America Speaks: Poll Data Summary, Vol. 15

American Medical Association

Visit www.researchamerica.org/partnership_opportunities for ways to support Research!America.  

Special Thanks to New and Renewing Research!Alliance Members 

New Members

United Therapeutics Corporation

Renewing Members

Alliance for Aging Research 
American Association of Colleges of Nursing 
American Brain Coalition 
American Society for Virology 
Blue Ridge Institute for Medical Research 
Brigham and Women's Hospital 
Caring for Carcinoid Foundation 
CDC Foundation 
Cold Spring Harbor Laboratory 
Columbia University 
Danaher Corporation 
The Endocrine Society 
Federation of American Societies of Experimental Biology 
Foundation for the National Institutes of Health 
Gilead Sciences, Inc. 
Harris Search Associates 
International & American Association of Dental Research 
Johns Hopkins Medicine 
Massachusetts General Hospital 
Memorial Sloan-Kettering Cancer Center 
NewYork-Presbyterian Hospital 
North Carolina Association for Biomedical Research 
Partners HealthCare System 
Perelman School of Medicine at the University of Pennsylvania 
Regeneron 
Society for Neuroscience 
Spina Bifida Association 
Texas Biomedical Research Institute 
University at Buffalo School of Medicine and Biomedical Sciences 
University of California, Irvine 
The University of Iowa 
University of Maryland School of Dentistry 
University of Nevada, Las Vegas School of Dental Medicine 
University of North Texas Health Science Center 
University of Pittsburgh School of Medicine 

Not yet a member? Join Research!America today at www.researchamerica.org/supportourwork.

Member Spotlight: The EveryLife Foundation for Rare Diseases

Founded: 2009
Location: Novato, Calif.
Mission: Accelerate biotech innovation for rare disease treatments through science-driven public policy. 

Currently, there are fewer than 400 approved treatments for 7,000 rare diseases affecting more than 30 million Americans. The science exists for many of these diseases to be treated; however, treatments may never be developed because of roadblocks in the development process, such as a lack of investment and a challenging regulatory environment. The EveryLife Foundation for Rare Diseases works with patient organizations, industry, academic scientists, the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to improve the clinical development process through efforts that include the CureTheProcess 2 campaign, the Rare Disease Scientific Workshop and legislation. And while the Foundation's primary focus is on regulatory issues, it also works to engage the rare disease community by spearheading programs that fulfill unmet need for patients and by supporting other organizations with similar goals.

Of the thousands of rare diseases impacting  Americans today, 95 percent have no treatment whatsoever, and many of the existing treatments are only able to address the symptoms of these ailments. While the National Institutes of Health's (NIH) support of basic research is an incredibly important component to finding cures for these types of diseases, the EveryLife Foundation for Rare Diseases also strives to create more incentives for industry to develop treatments.

The foundation's current campaign, CureTheProcess2, is a grassroots, patient-driven advocacy campaign to remove roadblocks in the drug development process, with three unique goals. The first of these is to encourage the FDA to accommodate a more scientifically rational and flexible application of safety data to allow U.S. patients to have access to early stage clinical trials. The second is to encourage the FDA to create more specialized drug review divisions and allow reviewers access to the latest science to enhance their understanding of the diseases they are reviewing. And finally, the new Orphan Product Extensions Now Accelerating Cures & Treatments (OPEN ACT) legislation would increase incentives for companies to explore the repurposing of already approved drugs for the treatment of rare diseases.

EveryLife also recognizes the compelling effect that sharing personal stories can have on policymakers, and works hard to make the patient voices of the rare disease community heard in Congress. From February 23-27, 2015, the Foundation, through its Rare Disease Legislative Advocates (RDLA) program will host Rare Disease Week on Capitol Hill, including Rare Disease Lobby Day, during which more than 200 advocates will have the opportunity to meet with members of Congress. The foundation will also relay the personal stories of patients unable to attend.

A new initiative for the foundation, Community Congress, is a membership-based program dedicated to bringing patient organizations, industry leaders and other rare disease stakeholder organizations together. The program provides the opportunity for members to learn about the foundation's scientific and policy goals, and help provide valuable insight on prioritizing future initiatives. The congress currently consists of three working groups - public policy, science/regulatory policy and newborn screening - that collaborate on these specific issues to provide an opportunity for continued engagement throughout the year to drive policy forward.

"We view our partnership with Research!America as vital in ensuring that the NIH and FDA are fully funded, so as to foster and accelerate our nation's innovation engine to bring life-saving therapies to patients," said Emil D. Kakkis, M.D., Ph.D., president, EveryLife Foundation for Rare Diseases.

For more information, visit www.everylifefoundation.org.

Action Alert

Advancing Medical Research and Innovation in FY16

The FY16 federal budget and appropriations process is an opportunity for advocates to shape investment in national priorities, such as medical research and innovation.

Sequestration is a continued reality for federal funding in FY16. It is up to advocates to share their stories of how stringent budget caps threaten real progress towards new treatments and cures.

Tell Congress: WE NEED CURES, NOT CUTS! 

Visit http://bit.ly/1JPLpND to learn more.

In the News

Media Matters

President's Budget & Precision Medicine

Several publications included quotes from Research!America President and CEO Mary Woolley about President Obama's FY16 budget proposal and the Precision Medicine Initiative including ForbesMedPage TodayScienceGenetic Engineering & Biotechnology NewsBaltimore SunThe Cancer Letter and Scientist.  "It is absolutely important to invest in initiatives that focus on precision medicine, Alzheimer's, antimicrobial resistance and other growing health threats, but these investments should supplement, not supplant, the imperative of making up for a decade's worth of lost ground," Woolley said.

Congressional Outlook 2015

In an article about the regulatory and policy landscape for medical research in 2015 in Bloomberg BNA, Woolley provided insights about research funding, big data and the 21st Century Cures initiative. "There are ways that legislation can remove barriers to innovation, and I would say the 21st Century Cures is on top of that," said Woolley.

Chemical & Engineering News featured comments from Ellie Dehoney, vice president of policy and advocacy, Research!America, about the prospects of increasing funding at the federal health agencies in FY16. "It is really up to advocates to make the case," said Dehoney.

Scientists in the 114th Congress

An article in The Wall Street Journal about the lack of scientists in Congress and the potential impact on federal research funding and policies included comments from Woolley. The article also appeared in NASDAQAllGov and Politics Cheat Sheet.

Woolley was also interviewed live on WATR-AM (Waterbury, CT) about the importance of having policymakers with a scientific background in Congress. "While it would be great to have more trained scientists in Congress what's even more important is that we have more ‘scientific-minded' members of Congress ... it's not about having a Ph.D., it's about having the interest," she said.

Sustain U.S. Lead in Biomedical Research

The Journal of the American Medical Association (JAMA)released a report demonstrating the urgency for increased investments in research to improve patient care in the U.S. and maintain global leadership in the sciences. Institute of Medicine (IOM) President Victor Dzau, M.D., a Research!America board member, and former IOM PresidentHarvey Fineberg, M.D., Ph.D., weighed in with an accompanying essay in JAMA, calling for new sources of research funding, strategic partnerships and a sound, long-term investment strategy.

Federal Investments Support Alzheimer's Research

In an op-ed published in the St. Louis Post Dispatch, Research!America board member Larry Shapiro, M.D., executive vice chancellor for medical affairs and dean at the Washington University School of Medicine in St. Louis, explained how federal government investments at the university have made it possible for researchers to identify an early diagnosis of Alzheimer's before symptoms are perceptible.

Restore NIH Funding

Ronald DePinho, M.D., president of the University of Texas MD Anderson Cancer Center, penned an op-ed in Roll Call urging Congress to increase the NIH budget to 
"re-establish our role as a global leader in medical research."

Newsletter Archives

February 2015 Research Advocate

Media Contacts

Suzanne Ffolkes
VP Communications
571-482-2710

Anna Briseño
Senior Communications Specialist
571-482-2737

We have health challenges in this country that science will provide answers for if given the chance and we haven't given science that opportunity
Mary Woolley, President and CEO, Research!America